EP1633316A4 - Anticorps se liant de maniere immunospecifique aux recepteurs trail - Google Patents

Anticorps se liant de maniere immunospecifique aux recepteurs trail

Info

Publication number
EP1633316A4
EP1633316A4 EP04775943A EP04775943A EP1633316A4 EP 1633316 A4 EP1633316 A4 EP 1633316A4 EP 04775943 A EP04775943 A EP 04775943A EP 04775943 A EP04775943 A EP 04775943A EP 1633316 A4 EP1633316 A4 EP 1633316A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
immunospecifically bind
trail receptors
trail
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04775943A
Other languages
German (de)
English (en)
Other versions
EP1633316A2 (fr
Inventor
Theodora Salcedo
Craig A Rosen
Vivian R Albert
Robin Humphreys
Tristan John Vaughan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1633316A2 publication Critical patent/EP1633316A2/fr
Publication of EP1633316A4 publication Critical patent/EP1633316A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
EP04775943A 2003-05-06 2004-05-05 Anticorps se liant de maniere immunospecifique aux recepteurs trail Withdrawn EP1633316A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46809203P 2003-05-06 2003-05-06
US49514003P 2003-08-15 2003-08-15
PCT/US2004/013900 WO2005016236A2 (fr) 2003-05-06 2004-05-05 Anticorps se liant de maniere immunospecifique aux recepteurs trail

Publications (2)

Publication Number Publication Date
EP1633316A2 EP1633316A2 (fr) 2006-03-15
EP1633316A4 true EP1633316A4 (fr) 2008-04-02

Family

ID=34197757

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04775943A Withdrawn EP1633316A4 (fr) 2003-05-06 2004-05-05 Anticorps se liant de maniere immunospecifique aux recepteurs trail

Country Status (3)

Country Link
EP (1) EP1633316A4 (fr)
CA (1) CA2524737A1 (fr)
WO (1) WO2005016236A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP2322624B1 (fr) 2005-03-25 2015-09-23 National Research Council Of Canada Procédé d'isolation de polypeptides solubles
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (fr) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Méthode de traitement d'amyloïdoses
EP2257301B1 (fr) 2008-03-03 2014-01-22 The University of Miami Immunothérapie à base de cellules cancéreuses allogéniques
CA2796339C (fr) 2010-04-15 2020-03-31 Abbott Laboratories Proteines de liaison a la beta amyloide
EP3533803B1 (fr) 2010-08-14 2021-10-27 AbbVie Inc. Anticorps anti-bêta-amyloïde
CA2916421A1 (fr) 2013-03-14 2014-09-25 Bayer Healthcare Llc Anticorps monoclonaux diriges contre un complexe antithrombine beta-heparine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150985A1 (en) * 1997-05-15 2002-10-17 Genentech, Inc. Apo-2 receptor
WO2002097033A2 (fr) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a des recepteurs de trail
WO2003054216A2 (fr) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a des recepteurs trail

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150985A1 (en) * 1997-05-15 2002-10-17 Genentech, Inc. Apo-2 receptor
WO2002097033A2 (fr) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a des recepteurs de trail
WO2003054216A2 (fr) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a des recepteurs trail

Also Published As

Publication number Publication date
WO2005016236A2 (fr) 2005-02-24
CA2524737A1 (fr) 2005-02-24
EP1633316A2 (fr) 2006-03-15
WO2005016236A3 (fr) 2007-06-14

Similar Documents

Publication Publication Date Title
EP1465925A4 (fr) Anticorps se liant de maniere immunospecifique a des recepteurs trail
HK1075470A1 (en) Antibodies that immunospecifically bind to trail receptors
EP1572874A3 (fr) Anticorps se liant de maniere immunospecifique a des recepteurs de trail
TWI366570B (en) Antibodies to madcam
GB0417384D0 (en) Antibodies to c-met
TWI365883B (en) Antibodies to m-csf
IL191340A (en) Monoclonal antibodies against e8o
HK1105126A1 (en) Monoclonal antibodies to progastrin
AU2002364954A8 (en) Antibodies that immunospecifically bind to blys
HK1096873A1 (en) Peptides and compounds that bind to thrombopoietin receptors
AU2003234706A8 (en) Antibodies that specifically bind to tl5
AU2003218456A8 (en) Antibodies that specifically bind to gmad
AU2003240822A8 (en) Antibodies that specifically bind to neurokinin b
EP1633316A4 (fr) Anticorps se liant de maniere immunospecifique aux recepteurs trail
AU2003256299A8 (en) Antibodies that specifically bind to reg iv
AU2003259835A8 (en) Antibodies that immunospecifically bind to trail receptors
EP1339426A4 (fr) Anticorps a liaison immunospecifique avec les recepteurs "trail"
AU2002352676A1 (en) Antibodies that immunospecifically bind to trail receptors
AU2003228483A8 (en) Antibodies that specifically bind to tr2
ZA200804254B (en) Human monoclonal antibodies to O8E

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051202

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/00 20060101ALI20070727BHEP

Ipc: A61K 39/395 20060101ALI20070727BHEP

Ipc: C12N 5/24 20060101ALI20070727BHEP

Ipc: C07K 16/00 20060101AFI20070727BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080228

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20080222BHEP

Ipc: A61P 37/00 20060101ALI20080222BHEP

Ipc: A61P 35/00 20060101ALI20080222BHEP

Ipc: A61K 39/395 20060101ALI20080222BHEP

Ipc: C12N 5/24 20060101ALI20080222BHEP

Ipc: C07K 16/28 20060101AFI20080222BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080515